Progenics Pharmaceutics (NASDAQ:PGNX) appoints board member David Mims as interim CEO, while the search continues for a permanent head of the company.
Mims previously served as president of U.S. specialty pharmaceuticals at privately held Aptalis Pharma during 2011-14, when it was acquired by Forest Laboratories.
Mims was one of five nominees of activist investor Velan Capital, which has opposed PGNX’s intended merger with Lantheus Medical Imaging (LNTH).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.